Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G

Lancet (London, England)7 Nov 2012Cited by 405 (Europe PMC)

PMID23141817DOI10.1016/s0140-6736(12)61267-7PepBankPUB-23141817

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than exenatide once weekly at week 26 (-1.48% versus -1.28%); exenatide once weekly did not meet the predefined non-inferiority criterion against liraglutide.
In plain wordsIn adults with type 2 diabetes, daily liraglutide lowered HbA1c more than weekly exenatide at 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline to week 26
Study
n = 776
Comparator
Exenatide once weekly 2 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · injection · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.48%
liraglutide 1.8 mg
HbA1c change
−1.28%
exenatide once weekly
Treatment difference
0.21%
exenatide minus liraglutide
Source sentences
Summary
The least-squares mean change in HbA(1c) was greater in patients in the liraglutide group (-1·48%, SE 0·05; n=386) than in those in the exenatide group (-1·28%, 0·05; 390) with the treatment difference (0·21%, 95% CI 0·08-0·33) not meeting predefined non-inferiority criteria (upper limit of CI <0·25%).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg).
Report a problemFND-2314181701
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide reduced HbA1c less than liraglutide and did not meet the predefined noninferiority criterion.
In plain wordsIn type 2 diabetes, exenatide reduced blood sugar less than liraglutide and failed the study's noninferiority criterion.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c change and noninferiority
Study
n = 776
Comparator
Liraglutide 1.8 mg once daily
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · injection · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.28%
exenatide, least-squares mean, n=390
HbA1c change
−1.48%
liraglutide, least-squares mean, n=386
Treatment difference in HbA1c change
0.21%
between groups
95% CI of treatment difference
0.08 to 0.33%
between groups
Source sentences
Summary
The least-squares mean change in HbA(1c) was greater in patients in the liraglutide group (-1·48%, SE 0·05; n=386) than in those in the exenatide group (-1·28%, 0·05; 390) with the treatment difference (0·21%, 95% CI 0·08-0·33) not meeting predefined non-inferiority criteria (upper limit of CI <0·25%).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs
Summary · context
The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.
Report a problemFND-2314181706
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea occurred in 21% with liraglutide 1.8 mg and 9% with exenatide once weekly.
In plain wordsIn adults with type 2 diabetes, nausea was more common with daily liraglutide than with weekly exenatide.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n = 911
Comparator
Exenatide once weekly 2 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg once daily · injection · 26 weeksAs given in this study (human).
Measurements
Nausea
21%
liraglutide 1.8 mg
Nausea
9%
exenatide once weekly
Source sentences
Summary
nausea (93 [21%] in the liraglutide group vs 43 [9%] in the exenatide group)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg).
Report a problemFND-2314181702
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, diarrhoea occurred in 13% with liraglutide 1.8 mg and 6% with exenatide once weekly.
In plain wordsIn adults with type 2 diabetes, diarrhoea was more common with daily liraglutide than with weekly exenatide.
Peptide
Liraglutide
Outcome
IncreaseDiarrhoea
Study
n = 911
Comparator
Exenatide once weekly 2 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg once daily · injection · 26 weeksAs given in this study (human).
Measurements
Diarrhoea
13%
liraglutide 1.8 mg
Diarrhoea
6%
exenatide once weekly
Source sentences
Summary
diarrhoea (59 [13%] vs 28 [6%])
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg).
Report a problemFND-2314181703
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, vomiting occurred in 11% with liraglutide 1.8 mg and 4% with exenatide once weekly.
In plain wordsIn adults with type 2 diabetes, vomiting was more common with daily liraglutide than with weekly exenatide.
Peptide
Liraglutide
Outcome
IncreaseVomiting
Study
n = 911
Comparator
Exenatide once weekly 2 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg once daily · injection · 26 weeksAs given in this study (human).
Measurements
Vomiting
11%
liraglutide 1.8 mg
Vomiting
4%
exenatide once weekly
Source sentences
Summary
vomiting 48 [11%] vs 17 [4%]
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg).
Report a problemFND-2314181704
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, 5% discontinued because of adverse events with liraglutide 1.8 mg and 3% with exenatide once weekly.
In plain wordsIn adults with type 2 diabetes, slightly more people stopped daily liraglutide because of side effects than weekly exenatide.
Peptide
Liraglutide
Outcome
IncreaseDiscontinuation because of adverse events
Study
n = 911
Comparator
Exenatide once weekly 2 mg
Outcome group
Adverse events · Whole body
Studied dose
1.8 mg once daily · injection · 26 weeksAs given in this study (human).
Measurements
Discontinuation due to adverse events
5%
liraglutide 1.8 mg
Discontinuation due to adverse events
3%
exenatide once weekly
Source sentences
Summary
24 (5%) patients allocated to liraglutide and 12 (3%) allocated to exenatide discontinued participation because of adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg).
Report a problemFND-2314181705
07HumanRandomized controlled trialSafety outcome
In type 2 diabetes, nausea occurred in 9% with exenatide versus 21% with liraglutide, and incidence decreased over time in both groups.
In plain wordsIn type 2 diabetes, nausea was less frequent with exenatide than liraglutide, and it became less frequent over time in both groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea
Study
n = 911
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · injection · 26 weeksAs given in this study (human).
Measurements
Patients with nausea
43 patients
exenatide
Patients with nausea
9%
exenatide
Patients with nausea
93 patients
liraglutide
Patients with nausea
21%
liraglutide
Source sentences
Summary
The most common adverse events were nausea (93 [21%] in the liraglutide group vs 43 [9%] in the exenatide group), diarrhoea (59 [13%] vs 28 [6%]), and vomiting 48 [11%] vs 17 [4%]), which occurred less frequently in the exenatide group and with decreasing incidence over time in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs
Summary · context
The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.
Report a problemFND-2314181707
08HumanRandomized controlled trialSafety outcome
In type 2 diabetes, diarrhoea occurred in 6% with exenatide versus 13% with liraglutide, and incidence decreased over time in both groups.
In plain wordsIn type 2 diabetes, diarrhoea was less frequent with exenatide than liraglutide, and it became less frequent over time in both groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDiarrhoea
Study
n = 911
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · injection · 26 weeksAs given in this study (human).
Measurements
Patients with diarrhoea
28 patients
exenatide
Patients with diarrhoea
6%
exenatide
Patients with diarrhoea
59 patients
liraglutide
Patients with diarrhoea
13%
liraglutide
Source sentences
Summary
The most common adverse events were nausea (93 [21%] in the liraglutide group vs 43 [9%] in the exenatide group), diarrhoea (59 [13%] vs 28 [6%]), and vomiting 48 [11%] vs 17 [4%]), which occurred less frequently in the exenatide group and with decreasing incidence over time in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs
Summary · context
The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.
Report a problemFND-2314181708
09HumanRandomized controlled trialSafety outcome
In type 2 diabetes, vomiting occurred in 4% with exenatide versus 11% with liraglutide, and incidence decreased over time in both groups.
In plain wordsIn type 2 diabetes, vomiting was less frequent with exenatide than liraglutide, and it became less frequent over time in both groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVomiting
Study
n = 911
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · injection · 26 weeksAs given in this study (human).
Measurements
Patients with vomiting
17 patients
exenatide
Patients with vomiting
4%
exenatide
Patients with vomiting
48 patients
liraglutide
Patients with vomiting
11%
liraglutide
Source sentences
Summary
The most common adverse events were nausea (93 [21%] in the liraglutide group vs 43 [9%] in the exenatide group), diarrhoea (59 [13%] vs 28 [6%]), and vomiting 48 [11%] vs 17 [4%]), which occurred less frequently in the exenatide group and with decreasing incidence over time in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs
Summary · context
The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.
Report a problemFND-2314181709
10HumanRandomized controlled trialSafety outcome
In type 2 diabetes, 3% receiving exenatide discontinued because of adverse events versus 5% receiving liraglutide.
In plain wordsIn type 2 diabetes, fewer participants stopped because of adverse events with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDiscontinuation because of adverse events
Study
n = 911
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Adverse events · Whole body
Studied dose
2 mg once weekly · injection · 26 weeksAs given in this study (human).
Measurements
Patients discontinuing because of adverse events
12 patients
exenatide
Patients discontinuing because of adverse events
3%
exenatide
Patients discontinuing because of adverse events
24 patients
liraglutide
Patients discontinuing because of adverse events
5%
liraglutide
Source sentences
Summary
24 (5%) patients allocated to liraglutide and 12 (3%) allocated to exenatide discontinued participation because of adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs
Summary · context
The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.
Report a problemFND-2314181710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02380521

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

University of Palermon = 60Jan 2015 to Nov 2016

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 8 Nov 2016

CompletedPhase 3Results postedNCT01029886

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

AstraZenecan = 912Jan 2010 to Apr 2011

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 9 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC